After months of wrangling, an agreement has finally been reached on a successor to the Voluntary Scheme for Branded Medicines Pricing and Access (VPAS), the system of revenue rebates used to limit ...
Leela Barham takes stock of the debate surrounding the UK’s current pricing and access deal that caps NHS spend on branded medicines, after a higher-than-expected payback rate for 2025. With the ABPI ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results